To include your compound in the COVID-19 Resource Center, submit it here.

J&J beats Street and reports Remicade dip on pricing

Johnson & Johnson (NYSE:JNJ) released on Tuesday 4Q17 figures and 2018 guidance which beat analysts' expectations despite a shortfall from sales of autoimmune drug Remicade infliximab. The pharma said Remicade demand was relatively stable

Read the full 340 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE